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ABSTRACT

Germline or somatic variation in the family of KMT2 lysine methyltransferases have been asso
ciated with a variety of congenital disorders and cancers. Notably, KMT2A-fusions are prevalent in
70% of infant leukaemias but fail to phenocopy short latency leukaemogenesis in mammalian
models, suggesting additional factors are necessary for transformation. Given the lack of addi
tional somatic mutation, the role of epigenetic regulation in cell specification, and our prior results
of germline KMT2C variation in infant leukaemia patients, we hypothesized that germline dysfunc
tion of KMT2C altered haematopoietic specification. In isogenic KMT2C KO hPSCs, we found
genome-wide differences in histone modifications at active and poised enhancers, leading to
gene expression profiles akin to mesendoderm rather than mesoderm highlighted by a significant
increase in NODAL expression and WNT inhibition, ultimately resulting in a lack of in vitro
hemogenic endothelium specification. These unbiased multi-omic results provide new evidence
for germline mechanisms increasing risk of early leukaemogenesis.

Introduction:
Paediatric cancers typically harbour relatively few
somatic mutations and frequently demonstrate
developmentally immature phenotypes, suggesting
a contribution from germline variation that might
result in aberrant tissue development [1]. Our
group previously found an enrichment of hetero
zygous germline missense mutations in KMT2C in
infants with leukaemia, compared to healthy con
trols [2]. This enrichment was independent of the
presence of KMT2A fusions, which are the hall
mark somatic mutation in infant leukaemia (>75%
of cases) and occur in utero [3]. In mammals,
somatic mutations of KMT2C and KMT2D are
associated with various malignancies [4], with
clear evidence for tumour suppressor roles [5,6].
Given the enrichment of KMT2C germline muta
tions in infant leukaemia and the genome-wide
epigenetic changes mediated by KMT2C, we
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hypothesized that germline KMT2C dysfunction
may adversely impact early developmental stages
of haematopoiesis, or perhaps mesoderm more
broadly.
The human COMPASS complexes are com
prised of highly conserved proteins from yeast to
humans that regulate gene expression through his
tone modifications [7,8]. Six different lysine
methyltransferases (KMT) anchor COMPASS
complexes in higher eukaryotes and are categor
ized into three subgroups based on homologies in
amino acid sequence and subunit composition:
SET1A (NM_014712), SET1B (NM_015048); 2]
MLL1/KMT2A
(NM_05933),
MLL2/KMT2B
(NM_014727); 3] MLL3/KMT2C, (NM_170606),
MLL4/KMT2D (NM_003482) [9]. While incom
pletely understood, the literature suggests that
paralogs exert non-overlapping and highly specia
lized functions by regulating the transcription of
discrete subsets of genes [9–11].
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However, KMT2C and KMT2D are partially
redundant in function [7,12], as both proteins
play an essential role in mediating monomethyla
tion at histone 3, lysine 4 (H3K4me1), primarily at
enhancers [13]. In contrast, recent studies have
highlighted other non-redundant and broadranging functions [14,15], such as a role for
KMT2C-specific transcriptional regulation that is
independent of its H3K4me1 activity on enhancers
[16]. Other reports describe KMT2C-mediated
histone trimethylation (H3K4me3) at promoters
[17,18]. With respect to early development,
KMT2C knockout (KO) mice die around birth
with no apparent morphological abnormalities,
while KMT2DKO mice showed early embryonic
lethality around E9.5 [19]. Loss of KMT2C in
mice also leads to aberrant myelopoiesis, causing
myeloid infiltration into lymphoid organs; how
ever, the loss of KMT2C alone was insufficient to
drive leukaemia [20]. The role of KMT2C has also
been characterized in nuclear receptor functioning
[17,21,22], metabolism [23] and circadian rhythms
[13,21].
While all SET and KMT2 proteins are epige
netic modifiers, each histone modification is asso
ciated with particular regulatory elements and
mediates specific functions, enabling complex con
trol over gene transcription [24]. KMT2C and
KMT2D are associated with H3K4me1, which is
a highly dynamic histone modification and corre
lates with cell type-specific gene expression pro
files, whereas H3K4me3 marks ‘active’ promoters
and is more invariant across cell types [reviewed
by 19, 24]. H3K4me1, along with H3K27ac, mark
‘active’ enhancers, while the combination of
H3K4me1 with H3K27me3 (mediated via poly
comb proteins) is a repressive mark associated
with ‘poised’ enhancers [25,26].
Currently, no comparative study exists describ
ing the role of KMT2C and its epigenetic regula
tion in human pluripotent stem cells (hPSC).
Pluripotent/precursor cells have multilineage
potential, at the precursor stage, cells have premarked genomic regions, which cooperate in
terminal transcriptional programmes for fate
determination [27–30] and may vary in
a quantifiable manner upon KMT2C dysfunction.
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We found that KMT2CKO hPSCs have a highly
variable epigenetic landscape compared to their
isogenic controls and are unable to complete the
endothelial to haematopoietic transition in vitro.
To interrogate this mechanism, we have per
formed a multi-omics analysis revealing that
KMT2CKO human pluripotent cells have
a transcriptional profile closer to mesendoderm
with a significant upregulation of NODAL/TGFβ
signalling.

Results
KMT2CKO hiPSCs retain pluripotency

Given our observation that infant leukaemia is
enriched in heterozygous germline missense muta
tions in KMT2C [2], we interrogated the role of
KMT2C in blood development by creating hPSC
models (hiPSC and hESC) with isogenic KMT2C
knockouts (Supp Figure 1a) amenable for directed
haematopoietic differentiation in vitro. Changes in
RNA and protein expression were specific to
KMT2C loss (Supp Figure 1b-d). We next asked
if the loss of KMT2C altered pluripotency. We
observed no morphological differences between
wild type and KMT2CKO cells (Supp Figure 2a)
as well as comparable immunostaining for pluri
potency markers Oct4, Sox2, and Nanog (Supp
Figure 2b,c). In addition, teratoma assays were
performed and the KMT2CKO line generated
a teratoma demonstrating all three germ layers
(Supp Figure 3), suggesting that loss of KMT2C
does not overtly alter the hiPSCs pluripotent state.

KMT2CKO human pluripotent cells fail to
specify hemogenic endothelium in vitro

To identify potential haematopoietic phenotypes
due to KMT2CKO, we next differentiated our
hiPSCs to mesoderm and haematopoietic progeni
tors using published protocols for haematopoietic
specification by Keller [31], which activates the Wnt
pathway via exogenous application of the GSK3
inhibitor, CHIR99021, to specify definitive haema
topoietic progenitors or the Wnt inhibitor, IWP2, to
enable NODAL/Activin signalling and the
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Figure 1. KMT2CKO pluripotent cells fail to specify hemogenic endothelium. hiPSCs (A panels) and H1 hESCs (B panels) with and
without KMT2C were directed through haematopoietic differentiation according to the protocol by Sturgeon et al. (Sturgeon CM, Nat
Biotech 2014). In all four cell lines, comparable amounts of CD34+/CD43- cells were specified (A1, A2, B1, B2). To differentiate
between arterial, venous and hemogenic endothelium, the CD34+ CD43- cells were further subsorted via CD73 and CD184. HE is
CD73-CD184- (boxes). In both KMT2CKO pluripotent lines, there is a failure to specify hemogenic endothelium at levels equivalent to
WT. Chi-square analyses found the decrease in hemogenic endothelium to be significant with p-values ≤0.01 for both human iPSCs
and ESCs as listed in Experimental Procedures under ‘Directed hematopoietic differentiation.’

specification of primitive haematopoiesis. As shown
in Figure 1.A1 and 1.A2, both WT and KMT2CKO
hiPSCs generate comparable numbers of CD34
+ CD43- progenitors (6.03% and 6.19%, respec
tively). However, progenitors of the arterial, venous,
and haematopoietic system are all CD34+ CD43-.

To differentiate these subpopulations, these cells are
then subsorted with CD73 and CD184. Hemogenic
endothelium (HE) is CD73-CD184-, while venous
endothelium is CD73+ CD184- and arterial
endothelium is CD73midCD184+ [31]. As shown
Figure 1.A3 and 1.A4, the KMT2CKO hiPSCs failed

EPIGENETICS
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Figure 2. RNA-seq reveals 319 differentially expressed genes in KMT2CKO hiPSCs. (a) Volcano plot for fold change in expression
(Y-axis) against the log of the fold change (X-axis). (b) Triplicates of RNA-seq from each cell line show consistent differences in gene
expression across 319 genes. (c) PCA analysis reveals that KMT2CKO cells more closely resemble mesendoderm than any of the three
germ layers.

to specify CD73-CD184- HE compared to WT. To
validate this observation, we established the same
KMT2CKO in H1 hESCs and took these cells
through the same directed differentiation
(Figure 1.B1-B4). H1 WT and KMT2CKO hESCs
exhibited the same morphology from pluripotency
through mesoderm (consistent with our hiPSC ter
atoma assay results) and embryoid body formation
(Supp Figure 4). We observed the same failure of
hemogenic endothelium specification (Figure 1, B4,
box). This failure was specific to KMT2C, as H1
hESCs transduced with a scrambled gDNA vector
did give rise to HE (Supp Fig 5). Furthermore,
KMT2CKO H1 ESCs showed a significant lack of
colony-forming capacity for all primitive

haematopoietic progenitors (Suppl Fig 6). In con
trast, the subpopulations of venous and arterial
endothelium were equivalent between WT and
KMT2CKO hiPSCs and hESCs. Given this clear
blood-specific phenotype due to KMT2C loss, we
sought to identify a mechanism.

RNAseq analysis identifies gene expression as
similar to mesendoderm

We performed transcriptome analysis to identify
gene expression differences and compare against
known cell types. Pairwise comparisons identified
319 differentially expressed genes upon
KMT2CKO (133 downregulated and 186
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Figure 3. Epigenome tracks showing histone modifications, ATAC-seq peaks and relative RNA expression for NODAL, its regulator
CER1 and two of its ligands, BMP4 and WNT3 in WT and KMT2CKO hiPSCs. Each gene demonstrates higher expression in the
KMT2CKO compared to WT (boxes in the RNA tracks) while NODAL, BMP4 and WNT3 show the expected decrease in H3K4me3 in the
KMT2CKO (boxes in the H3K4me3 tracks).

upregulated; Supp Table 1A,B) with a false discov
ery rate (FDR) <0.05 and log of fold change >2
(Figure 2a,b). Genes up/downregulated >10-fold in
KMT2CKO compared to WT are listed in Table 1.

In KMT2CKO, we observed the highest upregu
lated expression of NODAL, its ligands (BMP4,
WNT3) and its regulators (FST, CER1, MIXL1,
LEFTY1). Prior studies on human pluripotent

EPIGENETICS
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Figure 4. Schematic overview of how the lack of KMT2C-mediated histone modifications in hPSCs alters cell fate specification in vitro.
Table 1. Genes whose expression is increased or decreased
>10-fold in KMT2C KO.
Down- or upregulated
Down-regulated

Up-regulated

Rank
Gene
1
RPS4Y1
2
SPTSSB
3
UCMA
4
RHOH
5
AC009078.1
6
SMIM24
7
CXCL5
8
AP000688.2
9
RAMP3
10
MAGEH1
11
ZNF208
12 ZNF790-AS
1
NODAL
2
FST
3
CER1
4
BMP4
5
FOS
6
GLIPR1L1
7
HPGD
8
TSPAN18
9
GAD1
10
MIXL1
11
WNT3
12
MT2A
13
DUSP10
14
USP3
15
CYP26A1

Fold change
(FC)
−38.274
−16.984
−15.773
−15.440
−14.436
−13.782
−13.317
−11.542
−10.443
−10.297
−10.253
−10.048
22.946
21.084
15.480
15.207
14.426
12.508
12.191
11.758
11.664
11.172
10.734
10.447
10.062
10.038
10.012

Log(FC)
−3.920
−3.355
−2.970
−3.552
−4.149
−4.218
−3.577
−2.907
−3.008
−10.110
−2.930
4.010
3.306
5.027
2.998
2.847
2.164
3.240
2.290
5.901
3.566
4.397
2.590
2.192
2.050
2.461

cells have demonstrated that NODAL/TGFb con
tributes to the maintenance of pluripotency
[32,33] and is regulated via OCT4(POU5F1)/
SOX2 TF binding and blocks differentiation [34].
Collectively, these differentially expressed genes
are part of one or more tightly integrated gene
regulatory networks (Supp Fig 7). With these tran
scriptome data, RNA-seq read counts from human

embryonic stem cell lines; HUES64 or H1 were
obtained from ENCODE (https://www.encodepro
ject.org/) for each of the cellular phenotypes sur
veyed in the PCA plot shown in Figure 2c. From
our transcriptome data for the KMT2CKO and
WT lines, the top 100 differentially expressed
genes (Supp Table 2) according to adjusted
p values (not fold change) were compared against
the ENCODE data. From this analysis, we con
clude that the gene expression profile of
KMT2CKO cells is closest to that of mesendoderm,
suggesting that the lack of KMT2C prevents the
Table 2. Active enhancer transcription factor (TF) binding
motifs that are significantly enriched in either wild type (WT)
or KMT2C KO.
Enriched in
WT or KO
Enriched in
WT
Enriched in
KMT2C KO

Motif for which TF
Rank
binding site
1 OCT4-SOX2-TCFNANOG
2 OCT4
1 TAL1/SCL
2 AR-halfsite
3 ZFX
4 REST-NRSF
5 ASCL1
6 ATOH1
7 TCF12
8 TCF21
9 EBF1
10 NF1-halfsite
11 FOX-Ebox
12 SMAD4
13 SMAD2
14 FOXA1 (GSE26831)
15 FOXA1 (GSE27824)
16 MYOG
17 FOXA2
18 REPIN1/AP4

HOMER
P-value
1E-34
1E-34
1E-44
1E-21
1E-21
1E-20
1E-20
1E-18
1E-18
1E-15
1E-14
1E-14
1E-14
1E-14
1E-14
1E-14
1E-14
1E-14
1E-13
1E-13

TF family
subtype

Homeobox
bHLH
NR
ZF
ZF
bHLH
bHLH
bHLH
bHLH
EBF
CTF
Forkhead
MAD
MAD
Forkhead
Forkhead
bHLH
Forkhead
bHLH
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cells from gene expression necessary to fully com
mit to either mesoderm or endoderm.
KMT2CKO alters chromatin accessibility

We next performed ATAC-seq and compared
regions of differential chromatin landscape
between KMT2CKO and WT hiPSC lines. The
absence of KMT2C resulted in a substantial
decrease in ATAC-seq peaks at promoter regions
(a 19.83% decrease at promoters up to 3 kb of
a TSS), consistent with closed chromatin and
inaccessible TF binding sites. Further, this
decrease was followed by a commensurate
increase of 23.04% in ATAC-seq peaks at
introns, downstream sequences, and distal inter
genic regions (Supp Fig 8A,B) in the KMT2CKO
line, suggesting that KMT2C’s known activity at
enhancers and distal regulatory elements is
essential to first open specific promoters for TF
binding and subsequent gene expression. The
lack of KMT2C kept enhancers open for TF
binding rather than allowing promoter binding
sites to open.
To identify which genes may be regulated via
this mechanism, we next performed TF motif
enrichment within these differentially accessible
ATAC regions. Open chromatin in WT was sig
nificantly enriched for 87 different motifs (Supp
Table 3). Of these, binding sites for CTCF and
CTCFL were most significantly enriched followed
by binding sites for several homeobox (OCT4/
POU5F1, OCT6/POU3F1) and high mobility
group (SOX2, SOX3, SOX6, SOX10, SOX15)
TFs, which includes two of the Yamanaka factors
and presumably localized to promoter regions
lost upon KMT2CKO (Supp Fig 8A). In contrast,
the absence of KMT2C resulted in rearrangement
of available TF binding motifs resulting in main
tenance of OCT4/POU5F1 and SOX2 binding
sites, but a significant increase in binding sites
for the Zinc finger proteins of the cerebellum
(ZIC) and their reverse complement (‘Unknown
ESC element’) along with several ETS TF family
(ERG, FLI1, ETV1, ETV2, ETS1) binding sites
(Supp Table 4). Lim et al. previously established
that Zic proteins maintain pluripotency in mur
ine ESCs under the regulation of Oct4/Pou5f1,
Nanog and Sox2 [35], consistent with

Table 3. Poised enhancer transcription factor (TF) binding
motifs that are significantly enriched in either wild type (WT)
or KMT2C KO.
Enriched
in WT or
KO
Enriched
in WT
Enriched
in
KMT2C
KO

Motif for which TF binding HOMER
Rank
site
P-value
1 OCT4-SOX2-TCF-NANOG
1E-25
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

KMT2CKO
phenotype.

TAL1/SCL
ATOH1
FOXL2
FOXA2
REST-NRSF
TCF12
FOXA1 (GSE26831)
ASCL1
TCF21
FOX-Ebox
REPIN1/AP4
MYOG
‘Unknown ESC element’
(ZIC complementary
sequence
FOXA1 (GSE27824)
FOXP1
SMAD2
ZIC
OLIG2
EBF1
ZFX
AR-halfsite
NFY
LHX1
NeuroD1
SOX3
NF1-halfsite

cells

retaining

TF family
subtype

1E-59
1E-37
1E-32
1E-29
1E-27
1E-24
1E-24
1E-23
1E-21
1E-21
1E-21
1E-19
1E-19

bHLH
bHLH
Forkhead
Forkhead
ZF
bHLH
Forkhead
bHLH
bHLH
Forkhead
bHLH
bHLH
ZF

1E-19
1E-18
1E-17
1E-17
1E-16
1E-16
1E-16
1E-15
1E-15
1E-15
1E-14
1E-13
1E-13

Forkhead
Forkhead
MAD
ZF
bHLH
EBF
ZF
NR
NTF
Homeobox
bHLH
HMG
CTF

a

pluripotent

The histone modification landscape in hPSCs

ATAC-seq or DNA hypersensitivity mapping does
not distinguish between different types of regula
tory elements (active enhancers, poised enhancers,
and bivalent promoters), is biased, and provides
little information on domain level features [36].
Therefore, to characterize these regulatory regions,
we performed ChIPmentation for four histone
modifications in WT and KMT2CKO hPSCs. The
histone modifications defining ‘primed,’ ‘active’
and ‘poised’ enhancers as well as ‘bivalent’ versus
‘active’ promoters are listed in Experimental
Procedures and Supplementary Table 5. ‘Active’
enhancers (AE) correlate with tissue-specific gene
expression, while ‘poised’ enhancers (PE) correlate
with potential gene expression at subsequent
developmental stages [25,37,38].

EPIGENETICS

As shown in Supp Fig 9A, the proportion of
each histone modification was similarly distributed
across the genome of WT and KMT2CKO.
However, the absence of KMT2C resulted in
a variable distribution of histone modification
between cell lines. Given that AE are the primary
targets of KMT2C, differences were primarily
observed for H3K4me1 marks (80% difference)
and H3K27ac marks (87% difference) (Supp
Fig 9B,C). In contrast, H3K27me3 marks showed
a lesser difference of 56% while H3K4me3 marks
at promoters showed the least difference with only
19% of peaks different between wild type and
KMT2CKO (Supp Fig 9D,E, respectively).
(i) Comparison of the active enhancer land
scape: The active enhancer landscape is mainly
shaped by the cooperative binding of ubiquitous
and cell-type-specific TFs [39]. As KMT2C is
known to mediate the H3K4me1 at enhancers,
we first compared the active enhancer landscape
between wild type and KMT2CKO cells. As shown
in the Venn diagram of Supp Fig 10A, there were
a total of 29,161 active enhancer peaks called. Of
these, only 2,231 (7.7%) were independent of
KMT2CKO and shared between both lines. In
contrast, 19,311 active enhancer peaks were speci
fic to the KMT2CKO line, while 7,619 were speci
fic to wild type. Supp Fig 10B,C shows the results
of GO term analyses for the AE specific to WT
versus KMT2CKO, respectively. In general, these
results suggest movement away from cellular dif
ferentiation (WT) towards more functions asso
ciated with GTPase, RAS activity along with
cellular junction organization and function
(KMT2CKO).
To identify the putative functions of these
KMT2CKO-specific active enhancer subgroups,
we performed TF binding motif analysis (Table
2). In wild type, consistent with the pluripotent
status of the cells and the available TF binding
motif analysis from ATAC-seq, the only signifi
cantly enriched active enhancer motifs were for
the cooperative binding site for OCT4/POU5F1SOX2-TCF-NANOG and OCT4/POU5F1 alone.
In contrast, the absence of KMT2C demonstrated
a loss of open OCT4 TF binding sites and
a significant enrichment of 18 different active
enhancer TF binding motifs.
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(ii) Comparison of poised enhancers: Poised
enhancers (PE), marked by H3K4me1 and
H3K27me3, are thought to be incapable of driving
gene expression when cells are in a pluripotent
state [26]. However, the loss of H3K27me3,
coupled with the acquisition of H3K27 acetylation
(H3K27ac), endows these enhancers with gene
regulatory functions and converts PE to AE.
Given this background, we identified overlapping
H3K4me1 and H3K27me3 peaks to identify and
compare PE marks between wild type and
KMT2CKO pluripotent cells. In wild type hiPSCs,
we identified 4,134 unique overlapping H3K4me1
and H3K27me3 marks compared to a nearly
4.5-fold increase of 18,593 unique overlapping
marks in KMT2CKO hiPSCs. The absence of
KMT2C demonstrated the expected increase in
poised enhancers (Supp Fig 11A) with consider
able differences in genomic loci. With respect to
putative functional differences, GO terms asso
ciated with the PE marks specific to each hiPSC
line generally changed from developmental func
tions in wild type to ion transport functions in
KMT2CKO (Supp Fig 11B,C), supporting the
lack of ion transport function by KMT2C and its
broader role in guiding development.
On the global level, the substantial increase in
PE following KMT2C knockout suggested altera
tions in gene regulatory networks involved in dif
ferentiation and cell specification. These genome
signatures are binding sites for pioneer transcrip
tion factors and lineage determining transcription
factors [40–43]. To identify TF binding sites
within these differential regions, we applied motif
analyses for wild type-specific and KMT2CKOspecific PE signature (Table 3).
In wild type, consistent with our results from
ATAC-seq and AE ChIPmentation, the only sig
nificantly enriched PE motif was the cooperative
binding site for OCT4/POU5F1-SOX2-TCFNANOG (Table 3). In contrast, the absence of
KMT2C demonstrated a loss of PE binding sites
for OCT4 and a significant enrichment of 26 dif
ferent PE TF binding motifs. Specifically, we noted
that these motifs consisted primarily of binding
sites for regulators of classic WNT1/b-catenin sig
nalling (TAL1/SCL, ATOH1, TCF12, ASCL1)
along with multiple forkhead proteins (FOXL2,
FOXA2, FOXA1, FOX:Ebox, FOXP1). As pioneer
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TFs at PE are known to unmask chromatin
domains during development [44], this finding is
consistent with those of Wang et al., who found
FOX TFs bound to PE during specification of
hESC-derived endodermal lineage intermediates
[45], suggesting that knocking out KMT2C may
result in human pluripotent cells being primed for
endodermal fate specification.
(iii) Characterizing bivalent promoters.
Pluripotent cells are enriched for promoters har
bouring the activating H3K4me3 mark as well as
the repressive H3K27me3 mark, a state called
‘bivalency.’ While bivalent promoters are not
unique to pluripotent cells, they are enriched in
these cell types, mainly marking developmental
and lineage-specific genes, which are generally sta
tic but can be rapidly activated or repressed. While
KMT2C is not known to have a direct role in
establishing bivalency, a few studies have observed
that KMT2C maintains H3K4me3 marks [17,18].
We identified a total of 5,568 bivalent promoters
in WT and KMT2CKO cells (Supp Fig 12) without
significant differences in TF binding motifs, which
is consistent with KMT2C not having a clear role
in establishing bivalency but more of an impact at
distal regulatory elements.

Enhancers’ act synergistically to promote gene
expression:

We next sought to investigate the relationship
between enhancer status and gene expression. We
assigned each identified enhancer to the nearest
promoter, allowing a maximal distance of 500 kb
between enhancer and target promoter. As
expected, genes associated with AE show signifi
cantly higher average expression levels, followed
by those associated with primed enhancers, then
poised enhancers, and finally genes not associated
with a marked enhancer (Supp Fig 13A,B; Supp
Tables 6,7), regardless of WT or KMT2CKO.
Additionally, the more AE associated with
a given gene, that gene demonstrated significantly
higher expression levels (Supp Fig 13 C,D; Supp
Tables 8,9). These results support our interpreta
tion that differences in active and poised enhan
cers are correlated with gene expression
differences and that more active enhancers

associated with a given gene results in significantly
higher overall expression.
This is further visualized in Figure 3 showing
aligned ChIPmentation, ATAC-seq and RNA-seq
peaks for NODAL, its regulator CER1 and two
ligands, BMP4 and WNT3 compared between
WT and knockout. All four genes have significant
mRNA overexpression in KMT2CKO compared to
WT along with a decrease in trimethylation of
H3K4 and, to a lesser extent, H3K27. Supp Fig 7
shows the interconnected gene regulatory
network(s) that include these four genes along
with 30 others. Similar epigenome browser tracks
for the remaining genes are shown in Supp Fig 14.
Proteome and phospho-proteome suggest
heterogeneity between WT and KMT2CKO

Since proteins are the ultimate functional effectors
of activity in biological systems, we sought to
correlate our epigenetic and expression results
with an unbiased survey of global proteomic and
phospho-proteomic expression. KMT2CKO dis
played consistent changes in the basal proteomic
and phosphorylation status of proteins (Supp
Fig 15A-D). Among 678 differentially expressed
proteins, 331 proteins were upregulated, while
347 proteins were downregulated (Supp Fig 15B,
Supp Table 10A,B). Only 299 phospho-proteins
showed differential expression – 134 phosphopro
teins were upregulated, and 165 proteins were
down-regulated (Supp Fig 15D, Supp Table 11A,
B). As expected, KMT2C was one of the most
underexpressed proteins in both samples, and in
accordance with RNA-seq downregulation, one of
the most downregulated proteins was RPS4Y1
(logFC(−2.02); P-value 7.2 × 10−9) while, cur
iously, the most upregulated proteins were several
metallothioneins (MT1A/B/E/F/G/H/M/X) along
with LEFTY1 (logFC(0.93); P-value 5.0 × 10−5),
another NODAL regulator. To further compare
to our existing datasets (transcriptome and pro
teome), we correlated the normalized log10transformed transcriptome and proteome expres
sion values to each other. This showed
a significant (p < 2.2e-16), but relatively weak,
Pearson-correlation coefficient of 0.18 (Supp
Fig 15E). This weak correlation between transcript
and protein levels is consistent with our
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observation that KMT2CKO does not impact the
cells’ pluripotent status but impacts their ability to
differentiate. Overall, the types of over- and under
represented gene set terms were similar between
transcriptome, proteome and phospho-proteome
(Supp Figure 9A,B) and overlapped with RNAseq
GO analysis, suggesting that the transcriptome/
proteome co-processing of our samples did not
induce any significant biases in terms of functional
complexity. To test for possible large-scale sys
tematic compositional biases caused by KMT2C
deletion, we performed gene set enrichment ana
lysis via GAGE methodology from our differen
tially expressed proteome data with KEGG and
gene ontology biological processes pathway data
for WNT and NODAL pathways (Supp Table
12). Across three biological processes and the
WNT pathway as a whole, the p-value for each
analysis was ≤0.05, suggesting a pathway-specific
enrichment for a change of function. In sum, these
results suggest that deletion of KMT2C
reprogrammes the cis-regulatory elements that
may change the actual binding position of some
master regulator (e.g., TAL1) at these cisregulatory elements, thereby impacting terminal
differentiation.
Discussion

The canonical WNT/β-catenin pathway is essential
for multiple developmental milestones including
haematopoietic specification [31,46] and aberrant
Wnt signalling has been associated with subtypes
of leukaemogenesis [reviewed in 47]. Physiologic
Wnt signalling can also be regulated by KMT2A
[48], but in KMT2A-rearranged leukaemias, which
comprise more than 70% of infant leukaemia cases
[49], Wnt signalling is fully dependent upon
KMT2A [50]. Despite decades of model organism
research on KMT2A-rearranged leukaemias, these
fusions alone, when expressed at physiologic levels
without other mutations, very rarely (if ever)
induce a neo/perinatal leukaemia in murine mod
els that phenocopies human infant leukaemia [51–
53], suggesting additional factors were required for
infant leukaemogenesis. To that end, we previously
examined germline exomes from infant leukaemia
patients and found a significant enrichment of
missense
germline
variants
in
multiple
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COMPASS complex members, particularly
KMT2C [2].
Against this context, we hypothesized that the
missense germline KMT2C mutations in infant
leukaemia skews normal blood development from
the very start of mesoderm differentiation such
that the resulting haematopoietic progenitors are
more easily transformed with the addition of
a somatic driver, such as a KMT2A fusion. To
explore the role of KMT2C in pluripotent cells,
we focused on a multi-omic, proteomic and func
tional study in hPSCs and found that the absence
of KMT2C does not impair the pluripotent phe
notype, but does result in a heavily altered epige
netic landscape leading to altered gene and protein
expression and ultimately, a failure of hemogenic
endothelium or primitive haematopoietic specifi
cation in vitro, leaving the resulting cells with
a transcriptional profile closer to mesendoderm
than mesoderm (Figures 2,4). Our ATAC-seq
results for KMT2CKO demonstrated a global
reduction in open chromatin at promoters that
bind chromatin topology regulators CTCF and
CTCFL/BORIS. Enhancer-promoter interactions
are mediated by architectural proteins, such as
CTCF, MEDIATOR, and COHESIN, which regu
late the organization of topologically associated
domains (TADs) in a cell- and gene-specific man
ner during development [54–56]. More specifi
cally, CTCF is required for proper expression of
Hox gene clusters during differentiation [55].
CTCF deletion alters chromatin structure and sub
sequent transcription of myeloid-specific factors
[57] ultimately driving aberrant HOX gene tran
scription in AML [58].
Without KMT2C, open chromatin shifts to
accessibility for binding sites associated with the
zinc finger of the cerebellum (ZIC) family of C2H2
zinc finger TFs. This is consistent with a prior
report showing that KMT2C/D loss leads to
a global reduction of chromatin interactions at
enhancers in the ES cells [59]. The fact that we
do not find a commensurate increase of ZIC or
decrease in CTCF/CTCRL mRNA/protein expres
sion suggests that KMT2C (potentially as part of
its COMPASS complex) mediates histone modifi
cations that alter the chromatin landscape but does
not directly regulate transcription or translation of
either gene family.
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In contrast, murine models of Zic proteins have
demonstrated that these transcription factors are
essential for maintaining pluripotency of ES cells
[60], but can also inhibit canonical Wnt/b-catenin
signalling in vitro and in vivo [61]. Consistent with
our results, Zic2 was previously found to be
enriched at AE and PE in ES cells and is essential
for chromatin accessibility and regulation of tran
scriptional programmes during development
[60,62]. Furthermore, ZIC2 was shown to interact
with SMAD2/SMAD3 and cause early develop
mental NODAL-dependent transcriptional altera
tions at FOXA2 targets [63]. Deregulation of ZIC
proteins has been associated with at least 20 dif
ferent cancer types [reviewed in 64]. In some
cases, ZIC family members are overexpressed
while in others, DNA methylation results in
a lack of ZIC protein expression. The end result
is disruption of either the canonical Wnt/βcatenin, TGFβ, or sonic hedgehog pathways in
different cell types at different developmental
stages, thereby contributing to transformation.
We next annotated cis-regulatory elements
modified via KMT2C by using histone modifica
tion patterns for AE and PE, which endow cells
with the ability to interpret environmental cues
correctly [37,65]. Transcription factor binding at
active enhancers is a key determinant of tissuespecific gene expression [66–68] an essential step
to execute developmental decisions for proper
temporal and spatial control which is critical for
embryonic development and correct fate decisions.
We reasoned that uncovering the functionally rele
vant TFs associated with developmentally dynamic
enhancers would identify lineage-specific regula
tors in controlling haematopoietic specification.
Motif analysis of the KMT2C-dependent changes
in AE and PE further complemented the shift
towards open chromatin at ZIC binding sites, as
we noted a shift away from OCT4/POU5F1
enhancers towards enhancers associated with
NODAL and TGFβ signalling. Of the KMT2CKOspecific enriched AE and PE (Tables 3B, 4B),
nearly all are associated with NODAL/TGFβ, but
specifically ATOH1, ASCL1, TCF12, TAL1/SCL,
SMAD2, multiple FOX genes, along with the
same ZIC and its complementary TF binding

motif observed in our ATAC-seq results. This
strongly implies that the lack of KMT2C has
resulted in these pluripotent cells turning off
WNT/β-catenin in favour of NODAL/TGFβ
signalling.
This interpretation was further supported by tran
scriptome sequencing where the loss of KMT2C
resulted in the largest fold expression increase in
NODAL, itself, along with additional effectors: FST,
BMP4, CER1, GAD1, MIXL1, and ligands WNT3
and BMP4. NODAL has been shown to be necessary
for maintaining pluripotency in hESCs [69] as well
as inhibiting mesoderm differentiation [70] and pro
moting endoderm differentiation [71]. Indeed, the
KMT2CKO cells demonstrated a pluripotent pheno
type, behaved identically to their isogenic WT coun
terparts in vitro from day 0 to day 3, and then failed
to specify not only definitive hemogenic endothe
lium, all consistent with the increased NODAL
expression, but also primitive haematopoietic pro
genitors which require NODAL/Activin signalling,
suggesting that additional effectors remain inactive
in the KMT2CKO cells.
In summary, somatic mutations in KMT2C have
been implicated in various cancers and germline,
missense mutations have been associated with infant
leukaemia, which trace transformation to in utero
development [3]. Given the relationship between
paediatric cancers and aberrant developmental
mechanisms, we sought to interrogate the role of
KMT2C starting at pluripotency rather than focus
ing on transformation of terminally differentiated
haematopoietic cells. While this multi-omic and
functional assessment of KMT2C in human pluri
potent cells is unique and expansive, translational
interpretation to human cancer phenotypes should
be cautiously interpreted as germline or somatic
KMT2C mutations are heterozygous and almost
always missense, suggesting a hypomorphic, rather
than null, impact on protein function that likely
alters cellular behaviours in more subtle ways.
With respect to germline variability, we postulate
that such variation does not drive transformation,
but merely creates a more easily transformed cell
type such that when a stochastic driver mutation
(e.g., KMT2A-fusion) is present at a critical devel
opmental stage, transformation occurs. This model

EPIGENETICS

is consistent with other studies of aberrant develop
ment and early oncogenesis [1]. Future work will
further explore this hypothesis with additional func
tional studies in vitro and in vivo.

Experimental procedures
Wild type and isogenic KMT2CKO hPSCs

Reprogrammed human inducible pluripotent stem
cells (hiPSC) were generated from white blood
cells collected from a healthy human male by the
Washington University Genome Engineering and
iPSC Core (GEiC). From this control line, the
GEiC generated an isogenic, bi-allelic KMT2CKO
line via CRISPR-guided non-homologous endjoining using a guide RNA targeting exon 3,
resulting in truncation of the remaining 56 exons
(Supp Figure 1a). The same process was also used
for human embryonic stem cells (H1) (Wisconsin
Stem Cell Bank). Supp Figure 1b-d demonstrates
that the knockout of KMT2C was specific, com
pared to its paralogs, in hPSCs.

Teratoma assays

Teratoma assays were performed by the
Washington University Mouse Genetics Core in
the Division of Comparative Medicine (DCM)
using the protocol published by Nelakanti [72].
Briefly, 1 × 106 cells diluted in 50 mL of
Matrigel™ was injected bilaterally into the gastro
cnemius of two NOD-SCID IL2Rgammanull (NSG)
mice. After eight weeks, the mice were sacrificed,
and the muscles harvested for tumours. Tumours
only grew in one of the two mice, which were
evaluated independently by veterinary pathologists
at the DCM.
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RNA sequencing

Cells were cultured to 70% confluency and then
washed once with PBS, trypsinized and pelleted by
centrifugation at 500 g for 10 min at 4°C. Cell
pellets were transferred to the Genome
Technology
Access
Center
(GTAC)
at
Washington University for mRNA selection,
sequencing library preparation, and sequencing
on the Illumina NextSeq500 platform.
RNA-seq analysis

RNA-seq reads were aligned to the Ensembl
release 72 primary assemblies with STAR version
2.5.1a [73]. Gene counts were derived from the
number of uniquely aligned unambiguous reads
by Subread: feature count version 1.4.6-p5 [74].
All gene counts were then imported into the R/
Bioconductor package EdgeR [75], and TMM nor
malization size factors were calculated to adjust for
samples for differences in library size. Ribosomal
genes and genes not expressed in the smallest
group size minus one sample greater than one
count-per-million were excluded from further
analysis. The TMM size factors and the matrix of
counts were then imported into the R/
Bioconductor package Limma [76]. Weighted like
lihoods based on the observed mean-variance rela
tionship of every gene and sample were then
calculated
for
all
samples
with
the
voomWithQualityWeights [77]. The performance
of all genes was assessed with plots of the residual
standard deviation of every gene to their average
log-count with a robustly fitted trend line of the
residuals. Differential expression analysis was then
performed to analyse for differences between con
ditions, and the results were filtered for only those
genes with Benjamini-Hochberg FDR adjusted
p-values ≤0.05.

Directed haematopoietic differentiation

ChIPmentation

Directed haematopoietic differentiation of human
pluripotent stem cells was performed as published
by Sturgeon and colleagues [31]. Statistical ana
lyses of the flow sorted cells shown in Figure 1
were performed by Chi-Square analysis as docu
mented in the table below.

ChIPmentation was carried out as previously
described [78] with minor modifications. Briefly,
cells were washed once with PBS followed by fixa
tion using 1% formaldehyde in up to 1 ml PBS for
10 min at room temperature. Glycine was used to
stop the reaction. Cells were collected at 500 g for
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10 min at 4°C (subsequent work was performed in
a 4°C cold room and used ice-cold buffers unless
otherwise specified) and washed once with 150 µl
ice-cold PBS supplemented with protease inhibi
tors (Thermo Scientific #A32955). After that, fixed
cells were either stored at −80°C for future experi
ments or lysed in sonication buffer supplemented
with a protease inhibitor, as described, and then
sonicated in a Covaris microtube (AFA fibre
crimp-cap) with a Covaris E220 sonicator using
the following settings: Peak incident power: 200;
Duty factor: 10%; Cycles per burst: 200; Treatment
time: 150 seconds (or until the DNA fragments’
size is in the range of 250–700 bp). Following
sonication, equilibration buffer was added into
the lysate. Lysates were centrifuged at 14,000
RPM at 4°C for 10 minutes. Supernatant contain
ing the sonicated chromatin was transferred into
a 1.5 ml DNA LoBind Eppendorf tube for immu
noprecipitation. For each immunoprecipitation,
20 µl magnetic DynabeadTM Protein A (Life
Technologies) were washed twice and resuspended in 2X PBS supplemented with 0.1%
BSA. For each immunoprecipitation, 1 µg of the
appropriate antibody (described below) was added
and bound to beads by rotating at least 6 hours at
4°C. Blocked antibody and conjugated beads were
then placed on a DYNAL Invitrogen magnetic
bead separator, supernatant was aspirated, and
the sonicated lysate was added to the beads fol
lowed by overnight incubation at 4°C on a rotator.
Beads were washed as described in original proto
col at 4°C (in a cold room) with various buffers as
provided in the protocol. Beads were then resuspended in 25 µl tagmentation mix (19 µl tag
mentation buffer + 1 µl Tagment DNA enzyme
supplemented with 5 µl nuclease free water) from
the Nextera DNA Sample Prep kit (Illumina) and
incubated at 37°C for 10 minutes in a thermocy
cler. The beads were washed with appropriate buf
fer (150 µl) per the protocol and then transferred
into a 1.5 mL microfuge tube. Supernatant was
immediately aspirated, leaving beads attached to
the wall of the tube while in place on the magnetic
separator. Bead pellets were then resuspended with
45 µl elution buffer supplemented with proteinase
K (NEB) and incubated for 1 hour at 55°C and
then 8–10 hours at 65°C to revert formaldehyde
cross-linking. After placing on the DYNAL

Invitrogen magnetic bead separator, the superna
tant was transferred to a clean microfuge tube, and
the beads were discarded. Finally, DNA was pur
ified via MinElute kit (Qiagen). From this purified
DNA, qPCR was performed as described in the
protocol to estimate the optimum number of
enrichment cycles. The final enrichment of the
libraries was then performed according to protocol
and subsequently purified using AMPure XP beads
followed by a size selection to recover libraries
with a fragment length of 250–400 bp prior to
sequencing.

Antibodies used in ChIPmentation

ChIP antibodies were purchased from Diagenode:
H3K4me3
(#C15410003),
H3K4me1
(#C15410037),
H3K27ac
(#C15410174),
H3K27me3
(#C15410069),
Rabbit
IgG
(#C15410206).

ChIPmentation analysis

Biological replicates were prepared for each his
tone modification – H3K4me1, H3K4me3,
H3K27ac, and H3K27me3 – in both WT and
KMT2CKO hiPSC along with two replicates of
rabbit IgG as a negative control. Raw sequence
reads were processed using the ENCODE
Transcription factor and Histone ChIP-Seq pro
cessing pipeline (http://github.com/ENCODEDCC/chip-seq-pipeline2),
accessed
27 February 2019). The pipeline filtered and
mapped the reads to hg19, validated the quality
of the data, and generated fold change signal
tracks over the control samples using MACS2.
Peaks were further called using epic2 [79] using
a false discovery rate (FDR) of 0.05, enabling both
broad and narrow histone mark peaks to be effi
ciently identified. Motif search around enhancer
signal and bivalent promoters signal were con
ducted using homer v4.8.3 (http://homer.ucsd.
edu/homer/index.html). Identifying an enrichment
of differential peak-associated genes as called by
Gene Ontology (http://geneontology.org) was per
formed
using
Bioconductor
R
package
clusterProfiler v3.12.0 [80].
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ATAC-seq library preparation, sequencing, and
analysis

To map chromatin accessibility, we used the Assay
for Transposase Accessible Chromatin (ATACseq) protocol optimized by Semenkovich [81].
Sequence reads were demultiplexed and mapped
using bowtie (http://bowtie-bio.sourceforge.net/
index.shtml) to hg19. Peaks were identified, and
signal tracks were generated with MACS2 using
the ENCODE ATAC-seq pipeline (http://github.
com/ENCODE-DCC/atac-seq-pipeline), assessed
on 13 May 2019. Consistency among replicates
was assessed based on Irreproducible Discovery
Rates (IDR). Differential binding peaks between
KMT2CKO and wild type were identified with
the R package DiffBind using an FDR <0.05.
Signal tracks of fold enrichment were visualized
with the WashU Epigenome browser (https://epi
genomegateway.wustl.edu).
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ultrasonication using a Covaris S220X sonicator
(Peak Incident Power: 150 W, Duty Factor: 10%,
cycles/burst: 500, time: 8 min, temp: 4°C). The
protein content was determined by the bicincho
ninic acid (BCA) method as shown in Supp Table
13. For the reference pool, 60 µg from each sample
was combined and 2 × 250 µg was processed with
the samples. A protein aliquot (250 µg) was
digested with trypsin after reduction and alkyla
tion of disulphide bonds. Peptides were prepared
and labelled with tandem mass tag reagents prior
to off-line fractionation using high-pH reversed
phase chromatography [82]. Aliquots of the
twenty-five fractions (~0.5 μg) were analysed
using LC-MS. The 25 fractions were further com
bined to 13 fractions for phosphopeptide enrich
ment as previously described [82] and analysed by
LC-MS.
Nano-LC-MS

Definition of enhancers and promoters

As listed in Supp Table 5, promoters were defined
as non-overlapping −1kb and +1kb intervals
around transcription start sites (TSS). Enhancers
were defined by H3K4me1 peaks and were
assigned to their closest promoter, allowing for
a maximum distance of 500 kb. Active enhancers
were those overlapped with H3K27ac peaks.
Poised and primed enhancers were assigned to
promoters after excluding those associated with
any active enhancers. Poised enhancers overlapped
with H3K27me3, whereas primed enhancers did
not. Promoters were defined by H3K4me3 peaks
within 1kb of TSS. Bivalent promoters were
defined by the overlapping peak of H3K4me3
and H3K27me3.
Peptide preparation, isobaric labelling, and
off-line fractionation for LC-MS

The frozen cell pellets (~10 million cells) were
solubilized [82] in 0.5 mL of 8 M urea buffer
(8 M urea, 75 mM NaCl, 50 mM Tris (pH 8.0),
1 mM EDTA, 2 µg/mL aprotinin, 10 µg/mL leu
peptin, 1 mM PMSF, 1:100 vol/vol Phosphatase
Inhibitor Cocktail 2, 1:100 vol/vol Phosphatase
Inhibitor Cocktail 3, 10 mM NaF) with

The samples in 1% (vol/vol) aqueous FA were
loaded (2.5 µL) onto a 75 µm i.d. × 50 cm
Acclaim® PepMap 100 C18 RSLC column
(Thermo-Fisher Scientific) on an EASY nano-LC
(Thermo Fisher Scientific). The column was equi
librated using constant pressure (700 bar) with
11 μL of solvent A (1% (vol/vol) aqueous FA).
The peptides were eluted using the following gra
dient programme with a flow rate of 300nL/min
and using solvents A and B (1% (vol/vol) FA/
MeCN): solvent A containing 5% B for 5 min, i
ncreased to 23% B over 105 min, to 35% B over
20 min, to 95% B over 1 min and constant 95%
B for 19 min. The data were acquired in datadependent acquisition (DDA) mode. The MS1
scans were acquired with the Orbitrap™ mass ana
lyser over m/z = 350 to 1500 and resolution set to
70,000. Twelve data-dependent high-energy colli
sional dissociation spectra (MS2) were acquired
from each MS1 scan with a mass resolving power
set to 35,000, a range of m/z = 100–2000, an
isolation width of 1.2 m/z, and a normalized colli
sion energy setting of 32%. The maximum injec
tion time was 60 ms for parent-ion analysis and
120 ms for product-ion analysis. The ions that
were selected for MS2 were dynamically excluded
for 40 sec. The automatic gain control (AGC) was
set at a target value of 3e6 ions for MS1 scans and
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1e5 ions for MS2. Peptide ions with charge states
of one or ≥7 were excluded for HCD acquisitions.
Protein identification

The unprocessed MS data from the mass spectro
meter were converted to peak lists using Proteome
Discoverer (version 2.1.0.81, Thermo-Fisher
Scientific) with the integration of reporter-ion
intensities of TMT 10-plex at a mass tolerance of
±3.15 mDa. The MS2 spectra with charges +2, +3
and +4 were analysed using Mascot software [83]
(Matrix Science, London, UK; version 2.5.1).
Mascot was set up to search against a SwissProt
database of human (version June 2016, 20,237
entries) and common contaminant proteins
(cRAP, version 1.0 Jan. 1st, 2012, 116 entries),
assuming the digestion enzyme was trypsin/P
with a maximum of 4 missed cleavages allowed.
The searches were performed with a fragment ion
mass tolerance of 0.02 Da and a parent ion toler
ance of 20 ppm. Carbamidomethylation of
cysteine was specified in Mascot as a fixed mod
ification. Deamidation of asparagine, formation of
pyro-glutamic acid from N-terminal glutamine,
acetylation of protein N-terminus, oxidation of
methionine, and pyro-carbamidomethylation of
N-terminal cysteine were specified as variable
modifications. Peptide spectrum matches (PSM)
were filtered at 1% false-discovery rate (FDR) by
searching against a reversed database and the
ascribed peptide identities were accepted. The
uniqueness of peptide sequences among the data
base entries was determined using the principal of
parsimony. Protein identities were inferred using
a greedy set cover algorithm and the identities
containing ≥2 Occam’s razor peptides were
accepted [84].
Protein relative quantification

The processing, quality assurance, and analysis of
TMT data were performed with proteoQ (version
1.0.0.0, https://github.com/qzhang503/proteoQ),
a tool developed with the tidyverse approach
[85,86] under the free software environment for
statistical computing and graphics, R (R Core
Team (2019). R: A language and environment
for statistical computing. R Foundation for

Statistical Computing, Vienna, Austria. URL
https://www.R-project.org/)
and
RStudio
(RStudio Team (2016). RStudio: Integrated
Development for R. RStudio, Inc., Boston, MA
URL http://www.rstudio.com/). Briefly, reporterion intensities under 10-plex TMT channels were
first obtained from Mascot, followed by the
removal of PSM entries from shared peptides or
with intensity values lower than 1E3. Intensity of
PSMs was converted to logarithmic ratios at base
two, in relative to the average intensity of refer
ence samples within a 10-plex TMT. Under each
TMT channel, Dixon’s outlier removals were car
ried out recursively for peptides with greater
than two identifying PSMs. The median of the
ratios of PSM that can be assigned to the same
peptide was first taken to represent the ratios of
the incumbent peptide. The median of the ratios
of peptides was then taken to represent the ratios
of the incumbent protein.
To align protein ratios under different TMT
channels, likelihood functions were first estimated
for the log-ratios of proteins using finite mixture
modelling, assuming two-component Gaussian mix
tures (R package: mixtools: normalmixEM) [87].
The ratio distributions were then aligned in that
the maximum likelihood of the log-ratios is centred
at zero for each sample. Scaling normalization was
performed to standardize the log-ratios of proteins
across samples. To discount the influence of outliers
from either log-ratios or reporter-ion intensities, the
values between the 5th and 95th percentile of logratios and 5th and 95th percentile of intensity were
used in the calculations of the standard deviations.

Informatic and statistical analysis

Metric multidimensional scaling (MDS) and
Principal component analysis (PCA) of protein
log2-ratios were performed with the base
R function stats:cmdscale and stats:prcomp,
respectively. Heat-map visualization of protein
log2-ratios was performed with pheatmap
(https://rdrr.io/cran/pheatmap/). Linear modelling
was performed using the contrast fit approach in
Limma [76], to assess the statistical significance in
protein abundance differences between indicated
groups of contrasts. Adjustments of p-values for
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multiple comparisons were performed
Benjamini-Hochberg (BH) correction.

with

Highlights
● KMT2C KO in hPSCs causes epigenetic dif
ferences at active and poised enhancers.
● These differences result in increased NODAL
and decreased WNT signaling.
● KMT2C KO hPSCs expression profiling
resembles
mesendoderm
rather
than
mesoderm.
● KMT2C KO hPSCs fail to specify hemogenic
endothelium in vitro.
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hPSC: human pluripotent stem cell
hiPSC: human induced pluripotent stem cell
hESC: human embryonic stem cell
HE: hemogenic endothelium
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